Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | PPARD | Q03181 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1314001 | 0.81 | AGXT (0.42) | CYP3A4TSHRSMYD2HTTSMN1; SMN2 | |
| SCHEMBL304400 | 0.79 | PPARG (0.39) | CYP3A4PPARGPPARASMYD2HTT | |
| SCHEMBL4106972 | 0.79 | CYP3A4 (0.49) | CYP3A4TSHRCYP1A2 | |
| SCHEMBL9347235 | 0.78 | ESR1 (0.43) | CYP3A4PPARGCYP1A2 | |
| SCHEMBL14542685 | 0.78 | AGXT (0.43) | CYP3A4CYP1A2HTTSMN1; SMN2 | |
| SCHEMBL11934179 | 0.78 | TP53 (0.42) | CYP3A4TSHRPPARGPPARASMYD2 | |
| SCHEMBL5574150 | 0.78 | CYP3A4 (0.43) | CYP3A4TSHRCYP1A2 | |
| SCHEMBL2745018 | 0.77 | PPARG (0.41) | TSHRPPARGPPARAPPARD | |
| SCHEMBL9347236 | 0.77 | AGXT (0.33) | CYP3A4TSHRPPARGPPARAPPARD | |
| SCHEMBL4587307 | 0.77 | IDO1 (0.42) | TSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404650-B2 | Methods of treating cancer with doxazolidine and prodrugs thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2007102888-A2 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-0708660-A1 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002420-A2 | PRODRUGS OF PROTEIN TYROSINE KINASE INHIBITORS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD. (GB) | 1995-01-26 | — | — | WO | disclosed |
| EP-0236880-B1 | Penem derivatives | ERBA CARLO SPA (IT) | 1994-07-20 | — | — | EP | disclosed |
| US-4886793-A | PENICILLINS; HUMANS OR ANIMALS | FARMITALIA CARLO ERBA, S.R.L. (IT) | 1989-12-12 | — | — | US | disclosed |
| EP-0236880-A2 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135618-A1 | METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF | DNPEP, PEPD, PREP | CYP3A4 293/4885TSHR 3888/4885PPARG 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.